ArticleMolecular cancer therapeutics2022

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.

Thomas Ertveldt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.